我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

尼可地尔在冠脉痉挛患者中的疗效和安全性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第5期
页码:
542-545
栏目:
临床研究
出版日期:
2018-06-25

文章信息/Info

Title:
Efficacy and safety of nicorandil in the treatment of patients with coronary artery spasm
作者:
王汝涛; 刘 毅; 廉 坤; 夏陈海; 贺 媛; 陶 凌
(空军军医大学第一附属医院心血管内科，陕西 西安 710032)
Author(s):
WANG Ru-tao;  LIU Yi;  LIAN Kun;  XIA Chen-hai;  HE Yuan;  TAO Ling
(Cardiovascular Department, First Affiliated Hospital, Air Force Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
尼可地尔; 冠脉痉挛; 疗效性; 安全性
Keywords:
nicorandil;  coronary artery spasm;  efficacy;  safety
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨尼可地尔在治疗冠脉痉挛患者中的疗效及安全性。方法 通过冠脉造影筛选出符合冠脉痉挛的患者50例，随机分为对照组和试药组，对照组给予抗血小板、调脂等常规治疗，试药组在常规治疗的基础上加用尼可地尔5 mg（3次/d），观察两组临床疗效以及治疗前后内皮功能变化［NO含量与内皮素（ET）-1水平］及药物安全性。结果 试药组的治疗效果明显优于对照组（P<0.05），与治疗前相比，对照组治疗后NO含量增高（P<0.05），ET-1含量减低（P<0.05）；尼可地尔组治疗3个月后，NO含量显著增加（P<0.01），ET-1含量显著减低（P<0.01）。治疗3个月后，与对照组相比，试药组NO含量显著增高（P<0.01），试药组ET-1含量显著减低（P<0.01），试药组仅发生1例轻微头痛，可耐受。结论 尼可地尔在治疗冠脉痉挛患者中具有良好的疗效和安全性。
Abstract:
AIM To investigate the efficacy and safety of nicorandil in the treatment of patients with coronary artery spasm. METHODS 50 patients with coronary artery spasm were randomly divided into a control group and a treatment group. The control group was given routine therapy, including antiplatelet and lipid therapy and the treatment group had routine therapy combined with nicorandil 5 mg, 3/d. Clinical therapy effects of the two groups and endothelial function were determined (the content of NO and endothelin-1) before and after treatment and drug safety was observed. RESULTS Compared with the control group, the clinical effects were clearly superior in the treatment group (P<0.05). After treatment, the NO content was increased (P<0.05), and the content of ET-1 was decreased (P<0.05) in the control group; After 3 months of treatment with nicorandil, the content of NO was increased significantly (P<0.01) and the ET-1 content was significantly decreased (P<0.01). Compared with the control group, treatment with nicorandil for 3 months increased the NO content (P<0.01), and decreased the ET-1 content significantly (P<0.01). The treatment group had only 1 adverse effecxt of mild headache which was tolerated by the patient. CONCLUSION Nicorandil has good efficacy and safety in the treatment of patients with coronary artery spasm.

参考文献/References

[1]周建军,吴先明,胡景云.冠脉狭窄合并冠脉痉挛患者PCI的疗效观察[J].中国现代医生,2010,48(1):133.

[2]向定成，郑 鹏，何喜民，等.不同钙拮抗剂对冠状动脉痉挛患者疗效的比较[J].临床心血管杂志,2008,24(10):790-791.

[3]Sueda S,Kohno H,Fukuda H,et al.Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine[J].Angiology,2004,55(4):403-411.

[4]Kim MH,Park EH,Yang DK,et al.Role of vasopasm in acute coronary sydrome: insights from ergonovine stress echocardiology[J].Circ J,2005,69(1):39-43.

[5]JCS Joint Working Group.Guidelines for diagnosis and treatment of patients with vasospastic angina(coronary spastic angina)(JCS 2008):digest version[J].Cir J,2010,74(8):1745-1762.

[6]Hung MY,Hsu KH,Hung MJ,et al.Interactions among gender,age,hypertension and C-reactive protein in coronary vasospasm[J].Eur J Clin Invest,2010,40(12):1094-1103.

[7]向定成，曾定尹，霍 勇.冠状动脉痉挛综合征诊断与治疗中国专家共识[J].中国介入心脏病学杂志,2015,23(4):181-186.

[8]Horinaka S.Use of nicorandil in cardiovascular disease and its optimization[J].Drugs,2011,71(9):1105-1119.

[9]Ito H.Etiology and clinical implications of microvascular dysfunction in patients with acute myocardial infarction[J].Int Heart J,2014,55(3):185-189.

[10]莫凡睿，李 娟，楚罗湘. 冠状动脉无复流现象的机制及防治的研究进展[J].实用医学杂志,2015,31(14):2395-2397.

[11]Serizawa K,Yogo K,Aizawa K,et al.Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats[J].Cardiovasc Diabetol,2011,10:105.

[12]Kim SH,Kim EJ,Cheon WS,et al.Comparative study of nicorandil and a spasmolytic cocktail in prevent radial artery spasm during transradial coronary angiograghy[J].Int J Cardiol,2007,120(3):325-330.

[13]高 波，贺 莉，肖 杰，等.口服尼可地尔预防桡动脉途径介入诊疗中桡动脉痉挛作用的临床研究[J].临床心血管病杂志,2014,30(6):495-497.

[14]姚铁柱，马景涛，郭丽敏.尼可地尔治疗5 - 氟尿嘧啶诱发冠脉痉挛1例报道[J].山东大学学报(医学版), 2016,54(3):95-96.

备注/Memo

备注/Memo:
收稿日期：2018-01-26.通讯作者：贺媛，主治医师，博士,主要从事冠心病的基础研究 Email：heyuan820927@163.com 作者简介：王汝涛，主治医师，硕士 Email：274535870@qq.com
更新日期/Last Update: 1900-01-01